Payment overview · 2025
General Payments
$22,144.43
175 reported records · 24 companies
Healthcare provider profile · identity verified
John Jones, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · HAZARD, KY · NPI 1396974234
Verified facts
What the public records show
CMS Open Payments records show John Jones, D.O. received $22,144.43 in general payments during 2025 across 175 reported records.
Abbott Laboratories accounted for 73.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Brilinta, Creon, Eliquis, Farxiga, Jardiance, Kerendia, Korlym, Linzess, Mounjaro, Nurtec Odt, Otezla, Ozempic, Qulipta, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 370 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Korlym by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nurtec Odt by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16,309.74 | 73.7% | 32 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $3,671.50 | 16.6% | 28 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $406.74 | 1.8% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $300.66 | 1.4% | 23 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $264.83 | 1.2% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $172.72 | 0.8% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $149.44 | 0.7% | 11 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $123.44 | 0.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $121.21 | 0.6% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $87.26 | 0.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.34 | 0.4% | 7 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $73.73 | 0.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $71.57 | 0.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.78 | 0.2% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $42.90 | 0.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.98 | 0.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$35.04 | 0.2% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $27.60 | 0.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $22.72 | 0.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $21.81 | 0.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $21.67 | 0.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.98 | 0.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.11 | 0.1% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $14.66 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $14,800.00 | 16 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,262.50 | 2 |
| Food and Beverage | $2,910.84 | 148 |
| Travel and Lodging | $1,166.88 | 8 |
| Education | $4.21 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16,309.74 | 32 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $3,467.53 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $345.00 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $300.66 | 23 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $264.83 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $222.02 | 17 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $188.42 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $172.72 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $149.44 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $137.72 | 7 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $130.78 | 11 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $123.44 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $121.21 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $103.39 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $86.34 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $86.34 | 7 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $73.73 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $71.57 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $52.17 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.05 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $44.00 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $44.00 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $42.90 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $28.15 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $27.60 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 14 | exact normalized | Medicare Part D |
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 145 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 370 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 141 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 220 | exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 120 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 207 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 267 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 134 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
120 | 31 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
370 | 65 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
220 | 43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 31 |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
134 | 32 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
207 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
267 | 54 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1184 | 142 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1013 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 883 | 198 |
| Pantoprazole Sodium | Pantoprazole Sodium | 715 | 153 |
| Lisinopril | Lisinopril | 678 | 149 |
| Metoprolol Tartrate | Metoprolol Tartrate | 563 | 125 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 560 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 450 | 116 |
| Furosemide | Furosemide | 411 | 98 |
| Metformin Hcl | Metformin Hcl | 408 | 88 |
| Potassium Chloride | Potassium Chloride | 407 | 88 |
| Farxiga | Dapagliflozin Propanediol | 370 | 65 |
| Famotidine | Famotidine | 353 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 353 | 78 |
| Clonazepam | Clonazepam | 332 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 306 | 67 |
| Omeprazole | Omeprazole | 302 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 296 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 295 | 66 |
| Ondansetron Hcl | Ondansetron Hcl | 282 | 67 |
| Diclofenac Sodium | Diclofenac Sodium | 267 | 71 |
| Ozempic | Semaglutide | 267 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 261 | 79 |
| Losartan Potassium | Losartan Potassium | 242 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 230 | 59 |
| Kerendia | Finerenone | 220 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 211 | 43 |
| Alendronate Sodium | Alendronate Sodium | 207 | 52 |
| Mounjaro | Tirzepatide | 207 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 194 | 31 |
| Montelukast Sodium | Montelukast Sodium | 191 | 52 |
| Ibuprofen | Ibuprofen | 189 | 53 |
| Nifedipine Er | Nifedipine | 189 | 35 |
| Fenofibrate | Fenofibrate Nanocrystallized | 187 | 52 |
| Prednisone | Prednisone | 185 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 46 |
| Nitroglycerin | Nitroglycerin | 176 | 76 |
| Trazodone Hcl | Trazodone Hcl | 173 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 163 | 34 |
| Donepezil Hcl | Donepezil Hcl | 161 | 33 |
| Alprazolam | Alprazolam | 160 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 34 |
| Diazepam | Diazepam | 157 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 41 |
| Eliquis | Apixaban | 145 | 35 |
| Jardiance | Empagliflozin | 141 | 31 |
| Simvastatin | Simvastatin | 139 | 30 |
| Pregabalin | Pregabalin | 138 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 134 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 132 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 131 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 129 | 21 |
| Celecoxib | Celecoxib | 127 | 28 |
| Allopurinol | Allopurinol | 126 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 126 | 25 |
| Buspirone Hcl | Buspirone Hcl | 125 | 31 |
| Meclizine Hcl | Meclizine Hcl | 124 | 32 |
| Linzess | Linaclotide | 120 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 119 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 116 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 115 | 29 |
| Promethazine Hcl | Promethazine Hcl | 115 | 30 |
| Sucralfate | Sucralfate | 114 | 20 |
| Spironolactone | Spironolactone | 107 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 100 | 37 |
| Fluconazole | Fluconazole | 98 | 50 |
| Mirtazapine | Mirtazapine | 98 | 23 |
| Carvedilol | Carvedilol | 97 | 19 |
| Tramadol Hcl | Tramadol Hcl | 96 | 24 |
| Entresto | Sacubitril/Valsartan | 95 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 93 | 15 |
| Clonidine Hcl | Clonidine Hcl | 92 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 17 |
| Ezetimibe | Ezetimibe | 87 | 15 |
| Meloxicam | Meloxicam | 86 | 23 |
| Sertraline Hcl | Sertraline Hcl | 86 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 85 | 60 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 32 |
| Metformin Hcl Er | Metformin Hcl | 83 | 23 |
| Tradjenta | Linagliptin | 75 | suppressed |
| Januvia | Sitagliptin Phosphate | 74 | 15 |
| Nystatin | Nystatin | 72 | 31 |
| Bupropion Xl | Bupropion Hcl | 71 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 71 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 71 | 12 |
| Levofloxacin | Levofloxacin | 70 | 49 |
| Roflumilast | Roflumilast | 68 | suppressed |
| Amoxicillin | Amoxicillin | 67 | 47 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 36 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 66 | 24 |
| Atenolol | Atenolol | 65 | 14 |
| Trulicity | Dulaglutide | 65 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 64 | 13 |
| Gemfibrozil | Gemfibrozil | 63 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 16 |
| Bupropion Hcl | Bupropion Hcl | 61 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | suppressed |
| Bumetanide | Bumetanide | 57 | 14 |
| Finasteride | Finasteride | 57 | 12 |
| Memantine Hcl | Memantine Hcl | 57 | suppressed |
| Methocarbamol | Methocarbamol | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 51 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | 13 |
| Ranolazine Er | Ranolazine | 50 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 50 | 16 |
| Naproxen | Naproxen | 48 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 46 | 11 |
| Fenofibrate | Fenofibrate | 46 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | suppressed |
| Lorazepam | Lorazepam | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 44 | 13 |
| Ubrelvy | Ubrogepant | 44 | 12 |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 43 | suppressed |
| Vascepa | Icosapent Ethyl | 43 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 42 | 18 |
| Repatha Sureclick | Evolocumab | 42 | suppressed |
| Azithromycin | Azithromycin | 41 | 35 |
| Estradiol | Estradiol | 41 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Dutasteride | Dutasteride | 40 | suppressed |
| Cilostazol | Cilostazol | 39 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Nyamyc | Nystatin | 39 | 16 |
| Memantine Hcl Er | Memantine Hcl | 38 | suppressed |
| Premarin | Estrogens, Conjugated | 38 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 38 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 37 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 37 | 14 |
| Lidocaine | Lidocaine | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 13 |
| Lactulose | Lactulose | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 34 | suppressed |
| Vraylar | Cariprazine Hcl | 34 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Novolog | Insulin Aspart | 33 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Insulin Lispro | Insulin Lispro | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 17 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 30 | 17 |
| Colestipol Hcl | Colestipol Hcl | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Methimazole | Methimazole | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 21 |
| Colchicine | Colchicine | 28 | 11 |
| Glipizide | Glipizide | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 27 | suppressed |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 15 |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Armodafinil | Armodafinil | 24 | suppressed |
| Korlym | Mifepristone | 24 | suppressed |
| Otezla | Apremilast | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Xifaxan | Rifaximin | 24 | suppressed |
| Ibu | Ibuprofen | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | 15 |
| Digoxin | Digoxin | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 13 |
| Lokelma | Sodium Zirconium Cyclosilicate | 16 | suppressed |
| Qulipta | Atogepant | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Daptomycin | Daptomycin | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $22,144.43 · 175 records | Abbott Laboratories | AIRSUPRA, AREXVY, Auvelity, BRILINTA, CREON, Dexcom G6 Transmitter, ELIQUIS, EVENITY, Epclusa, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, Kerendia, Korlym, LINZESS, MAVYRET, MINIMED 780G, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Omnipod, Ozempic, Prolastin-C Liquid, QULIPTA, REPATHA, Rybelsus, SPRAVATO, TONMYA, TRELEGY ELLIPTA, TZIELD, UBRELVY, VERQUVO, ZAVZPRET, ZEPBOUND, ZORYVE | 26 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error